Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.68 |
| ▸ | MAOA | P21397 | 1/20 | 0.68 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.62 |
| ▸ | CASP1 | P29466 | 2/20 | 0.62 |
| ▸ | CASP7 | P55210 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.62 |
| ▸ | FLT3 | P36888 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL742193 | 0.88 | MIF (0.68) | MAOBMAOAAKR1B1ALDH1A1KDM4E | |
| SCHEMBL25777700 | 0.86 | CA12 (0.59) | MAOBMAOAAKR1B1ALDH1A1KDM4E | |
| SCHEMBL1066982 | 0.86 | TAS1R3 (0.56) | MAOBMAOAAKR1B1ALDH1A1KDM4E | |
| SCHEMBL2082039 | 0.86 | KDM4E (0.55) | MAOBMAOAAKR1B1ALDH1A1KDM4E | |
| SCHEMBL2255398 | 0.85 | FLT3 (0.61) | MAOBMAOAAKR1B1ALDH1A1KDM4E | |
| SCHEMBL30493800 | 0.85 | FLT3 (0.61) | MAOBMAOAAKR1B1ALDH1A1KDM4E | |
| SCHEMBL10395770 | 0.84 | CA12 (0.56) | MAOBMAOAAKR1B1ALDH1A1KDM4E | |
| SCHEMBL30427013 | 0.84 | PIM1 (0.60) | MAOBMAOAAKR1B1ALDH1A1KDM4E | |
| SCHEMBL5023676 | 0.84 | MAOB (0.69) | MAOBALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL2084419 | 0.84 | PIM1 (0.60) | MAOBMAOAAKR1B1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1093367-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | claimed |
| EP-1093367-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-25 | — | — | EP | claimed |
| WO-1999066925-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-29 | — | — | WO | claimed |
| US-20250228944-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-12171831-B2 | Compounds and methods for the targeted degradation of bromodomain- containing proteins | ARVINAS OPERATIONS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| CN-116783160-A | Libraries of compounds | 中外制药株式会社 | 2023-09-19 | — | — | CN | disclosed |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11554171-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | ARVINAS OPERATIONS, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| EP-0869787-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997024119-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| US-5434186-A | Antiinflammatory agents | HOFFMANN-LA ROCHE INC. (US) | 1995-07-18 | — | — | US | disclosed |
| US-5273999-A | A 4-keto-boroalkyleneoxychroman or 2,3-dihydrobenzofuran derivative | HOFFMANN-LA ROCHE INC. (US) | 1993-12-28 | — | — | US | disclosed |
| CN-1071423-A | BICYCLIC CARBOXYLIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 1993-04-28 | — | — | CN | disclosed |
| EP-0531823-A1 | Bicyclic carboxylic acid derivatives as anti-inflammatory agents | F. HOFFMANN-LA ROCHE AG (CH) | 1993-03-17 | — | — | EP | disclosed |
| EP-0150966-B1 | BENZOPYRAN DERIVATIVES, COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION | FISONS plc (GB) | 1989-07-12 | — | — | EP | disclosed |
| US-4670452-A | Dioxo dibenzopyrans and anti-allergic use thereof | FISONS PLC (GB) | 1987-06-02 | — | — | US | disclosed |
| EP-0150966-A2 | Benzopyran derivatives, compositions containing them and processes for their preparation | FISONS plc (GB) | 1985-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11554171-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | BRPF3, STUB1, BRDT | MAOB 2860/4885MAOA 2892/4885AKR1B1 2683/4885 |
| US-12171831-B2 | Compounds and methods for the targeted degradation of bromodomain- containing proteins | BRPF3, STUB1, BRDT | MAOB 2860/4885MAOA 2892/4885AKR1B1 2683/4885 |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | MAOB 2860/4885MAOA 2892/4885AKR1B1 2683/4885 |
| US-20250228944-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | MAOB 2860/4885MAOA 2892/4885AKR1B1 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.